Pfizer (PFE) Non Operating Income (2010 - 2012)
Pfizer (PFE) posted quarterly Non Operating Income of $293.0 million for Q3 2012, up 2.09% year-over-year from $287.0 million in Q3 2011, and down 5.18% quarter-over-quarter from $309.0 million in Q2 2012.
Pfizer (PFE) Non Operating Income (2010 - 2012) Analysis & Trends
Pfizer (PFE) has reported Non Operating Income for 3 consecutive years, with $293.0 million the latest figure, recorded in Q3 2012.
- In Q3 2012, Non Operating Income rose 2.09% year-over-year to $293.0 million; the TTM figure through Jul 2012 stood at $1.2 billion (down 10.3% YoY), while the FY2011 annual figure was $1.2 billion, down 12.33% from the prior year.
- Non Operating Income declined to $293.0 million in Q3 2012 per PFE's latest filing, from $309.0 million in the prior quarter.
- Across five years, Non Operating Income topped out at $410.0 million in Q2 2010 and bottomed at $270.0 million in Q4 2011.
- Historically, Non Operating Income has averaged $322.0 million across 3 years, with a median of $311.0 million in 2011.
- Annual changes were most pronounced in 2011 — Non Operating Income dropped 23.73% — and 2012, when it grew 2.09%.
- Pfizer's Non Operating Income stood at $354.0 million in 2010, then retreated by 23.73% to $270.0 million in 2011, then advanced by 8.52% to $293.0 million in 2012.
- Business Quant data shows PFE's Non Operating Income at $293.0 million in Q3 2012, $309.0 million in Q2 2012, and $270.0 million in Q4 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -73.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 387.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 1, 2012 | 293.00 Mn |
| Apr 1, 2012 | 309.00 Mn |
| Dec 31, 2011 | 270.00 Mn |
| Oct 2, 2011 | 313.00 Mn |
| Jul 3, 2011 | 287.00 Mn |
| Apr 3, 2011 | 353.00 Mn |
| Dec 31, 2010 | 354.00 Mn |
| Oct 3, 2010 | 327.00 Mn |
| Jul 4, 2010 | 304.00 Mn |
| Apr 4, 2010 | 410.00 Mn |